Search - tctmd.com

Displaying 81 - 100 of 1898

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Presenter: Eugene H. Blackstone, Robert W. Yeh, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Presenter: Eugene H. Blackstone, Robert W. Yeh, Tracy Y. Wang

October 30, 2016

Presentation TCT 2016

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Martin B. Leon

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Presenter: Eugene H. Blackstone, Robert W. Yeh, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Presenter: Dean J. Kereiakes, Pieter C. Smits, Lisette Okkels Jensen

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Atherectomy

Presenter: Schuyler Jones, Misti Malone, Brad Martinsen, PhD

October 30, 2016

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

FDA Perspectives

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Levels of Evidence: Single-center vs Multicenter Trials

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Overview of the Clinical Trials for Atherectomy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content